Clinical Trial

Activity of Mouthwashes Againgst Entamoeba Spp.

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The amoeba Entamoeba gingivalis colonizes the human oral cavity, where it can actively destroy tissue and cause local inflammation. Currently, there is no standard treatment for E. gingivalis infection. Even during treatment for periodontitis, there is no specific treatment targeting E. gingivalis, although this could significantly improve the effectiveness and long-term results of periodontitis therapy. Octenidine is an antiseptic agent used for disinfecting skin, mucous membranes, and wounds. It is effective against bacteria, fungi, and some viruses. octenident® is a commercially available cosmetic mouthwash containing octenidine as the active ingredient. Its efficacy against Entamoeba spp. will be tested in vitro. Because E. gingivalis is very difficult to cultivate under laboratory conditions, and in vitro testing may not be feasible, the effect of using the mouthwash octenident® (cosmetic product) twice daily for 30 seconds over a 7-day period on the quantity of E. gingivalis will be evaluated in healthy volunteers using quantitative real-time PCR, a technique enabling the comparison of E. gingivalis DNA before and after the use of octenident®.
Trial Details
NCT Number NCT07210814
Lead Sponsor Medical University of Vienna
Conditions Parasite Infestation
Enrollment 40 participants
Start Date 2025-10-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-07